ResVita Bio Appoints John D. Doux, M.D., M.B.A., to Board of Directors
Summary
ResVita Bio appointed John D. Doux, M.D., M.B.A., to its Board of Directors. The company is preparing to advance RVB-003 into the clinic for Netherton Syndrome while expanding its topical cell therapy platform across rare skin diseases. Doux brings dermatology, rare disease, and investment experience that supports the company’s development strategy. The announcement highlights ResVita’s broader pipeline goals and its focus on disease-modifying therapies for underserved patients.
Classifications
industries
No industries detected
applications
No applications detected
AskAI Classifications
Labels
No AI classifications detected